01 5Resolor/Motegrity
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 50
2018 Revenue in Millions : 0
Growth (%) : New launch
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 99
2019 Revenue in Millions : 51
Growth (%) : 93
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 108
2020 Revenue in Millions : 95
Growth (%) : 23
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 125
2021 Revenue in Millions : 108
Growth (%) : 16
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 139
2022 Revenue in Millions : 126
Growth (%) : 25
LOOKING FOR A SUPPLIER?
